Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 174

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 174
---
 the calculation of diluted net loss per share because such shares are anti-dilutive:

    For the three and nine months ended September 30,  
    For the three months 
ended 
September 30, 
2024 
and for the period from February 14, 2024 through September 30,  
    For the period from January 1, 2024 through February 14, 

    2025  
    2024  
    2024 

    (Successor)  
    (Successor)  
    (Predecessor) 
  
    Conversion of convertible preferred stock issued and outstanding 
     2,644,267  
     42,385  
     900 
  
    Conversion of convertible preferred stock underlying convertible preferred stock warrants 
     -  
     24,898  
     60 
  
    Exercise of warrants for common stock 
     159,724  
     9,153  
     - 
  
    Common stock underlying outstanding options (2024 Plan) 
     74,151  
     1,329  
     25 

     2,878,142  
     77,765  
     985 

Restricted common stock
can be issued to directors, executives or employees of the Company and are subject to time-based vesting. These potential shares are
excluded from the computation of basic loss per share as these shares are not considered outstanding until vested. No unvested restricted
common stock awards were issued or outstanding during the nine months ended September 30, 2025 or the nine month period ended September
30, 2024.

NOTE 5 – PROPERTY AND
EQUIPMENT

Property and equipment, net, consisted of the
following as of September 30, 2025 and December 31, 2024:

    September 30,  
    December 31, 

    2025  
    2024 

    (Successor)  
    (Successor) 
  
    Laboratory equipment 
    $2,507,839  
    $2,507,839 
  
    Computers 
     38,323  
     38,323 
  
    Furniture 
     8,429  
     8,429 
  
    Total cost 
     2,554,591  
     2,554,591